Vaccine Effectiveness of a Bivalent RSV Prefusion F Protein-Based Vaccine for Preventing RSV Hospitalizations in Adults (DAN-RSV)

May 27, 2026 updated by: Tor Biering-Sørensen

A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above

The purpose of this pragmatic randomized trial is to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine (RSV vaccine) in adults. Participants will be randomized 1:1 to either RSV vaccine or no RSV vaccine.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

The study is a pragmatic, registry-based, open-label, individually randomized trial. Administrative health registries will be used for data collection including baseline information, follow-up data, and safety monitoring. The study aims to randomize a total of 690,000 participants. Participants will be individually randomized 1:1 to receive either a bivalent RSV prefusion F vaccine (RSV vaccine) or no RSV vaccine. The trial is designed to assess the vaccine effectiveness of the RSV vaccine vs. no RSV vaccine on RSV-related and all-cause cardio-respiratory outcomes.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
690000

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Denmark
      • Copenhagen, Denmark, 2900
        • Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte
      • Søborg, Denmark, 2860
        • Danske Lægers Vaccinations Service
  • Spain
    • A Coruña
      • Santiago de Compostela, A Coruña, Spain
        • General Public Health Directorate of Galician Health Service

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria

  • Age 18 years and above
  • Informed consent form has been signed and dated

Exclusion Criteria:

  • There are no specific exclusion criteria for this study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: RSV prefusion F protein-based vaccine (RSV vaccine)
RSV vaccine single injection at day 0
Biological: RSV prefusion F protein-based vaccine
For this arm, the RSV prefusion F protein-based vaccine Abrysvo® will be used
Other Names:
  • RSVpreF vaccine
No Intervention: No RSV vaccine (control)
Control arm, no RSV vaccine

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Hospitalization for RSV-related respiratory tract disease
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
RSV-related respiratory tract disease hospitalization
Time Frame: ≥14 days after actual vaccination date/ booked information visit date up to 8 months
Primary outcome evaluated among the as-treated study population with balanced follow up time between study arms
≥14 days after actual vaccination date/ booked information visit date up to 8 months
Hospitalization for RSV-related lower respiratory tract disease
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause respiratory tract disease hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related cardio-respiratory hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause cardio-respiratory hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause lower respiratory tract disease hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause mortality
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization for RSV-related respiratory tract disease by age groups
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratified by age groups (18-59, 60-74 years and 75+ years)
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related respiratory tract disease hospitalization (as-treated)
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Among the as-treated study population with balanced follow up time between study arms
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization for RSV-related respiratory tract disease in subsequent seasons
Time Frame: From June 1, 2025 up to 12 months (2025/2026 season) and June 1, 2026 up to 12 months (2026/2027 season)
Subsequent seasons (2025/2026 and 2026/2027 RSV seasons)
From June 1, 2025 up to 12 months (2025/2026 season) and June 1, 2026 up to 12 months (2026/2027 season)

Other Outcome Measures

Other Outcome Measures

For clinical trials, a planned measurement described in the protocol that is used to determine the effect of an intervention/treatment on participants. For observational studies, a measurement or observation that is used to describe patterns of diseases or traits, or associations with exposures, risk factors, or treatment. Types of outcome measures include primary outcome measure and secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Hospitalization for RSV-related respiratory tract disease stratified by RSV type
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratification by RSV type (A or B)
≥14 days after initially booked vaccination/ information visit date up to 8 months
Total length of hospital stays due to respiratory tract infection with RSV infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV or pneumonia hospitalization [composite endpoint]
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Based only on ICD-10 codes
≥14 days after initially booked vaccination/ information visit date up to 8 months
Pneumonia hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Any hospitalization with RSV infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Cardiovascular disease hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization requiring mechanical ventilation
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Intensive care unit hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Myocardial infarction hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Heart failure hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Stroke hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Influenza hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
COVID-19 hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization for pneumococcal disease
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Any infectious disease hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
MACE (composite endpoint)
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Non-fatal myocardial infarction, heart failure hospitalization, stroke, and cardiovascular death
≥14 days after initially booked vaccination/ information visit date up to 8 months
Laboratory-confirmed RSV infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Laboratory-confirmed influenza infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Laboratory-confirmed pneumococcal infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Laboratory-confirmed COVID-19 infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Cardio-respiratory mortality
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Respiratory mortality
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Cardiovascular mortality
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
In-hospital mortality
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
30-day mortality following hospital discharge for primary endpoint
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related respiratory tract disease hospitalization by chronic obstructive pulmonary disease status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Primary endpoint in patients with chronic obstructive pulmonary disease
≥14 days after initially booked vaccination/ information visit date up to 8 months
New-onset dementia
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 10 years
≥14 days after initially booked vaccination/ information visit date up to 10 years
RSV-related respiratory tract disease hospitalization by immunocompromised status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratified by immunocompromised status. Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related lower respiratory tract disease hospitalization by immunocompromised status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratified by immunocompromised status. Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause respiratory tract disease hospitalization by immunocompromised status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratified by immunocompromised status. Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause lower respiratory tract disease hospitalization by immunocompromised status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratified by immunocompromised status. Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related respiratory tract disease hospitalization by severe immunocompromised status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratified by severe immunocompromised status. Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause respiratory tract disease hospitalization by severe immunocompromised status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Stratified by severe immunocompromised status. Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
Atrial fibrillation hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization for any cardiac arrythmia
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization for pericarditis
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization for myocarditis
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
Asthma exacerbation hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related respiratory tract disease hospitalization by hepatic or renal impairment status
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
Among those with hepatic or renal impairment at baseline. Analysis will be carried out as outlined in C3761080, EU PASS register number EUPAS1000000480
≥14 days after initially booked vaccination/ information visit date up to 8 months
Hospitalization for RSV-related lower respiratory tract disease in subsequent 2025/2026 and 2026/2027 RSV seasons
Time Frame: From June 1, 2025 up to 12 months (2025/2026 season) and June 1, 2026 up to 12 months (2026/2027 season)
From June 1, 2025 up to 12 months (2025/2026 season) and June 1, 2026 up to 12 months (2026/2027 season)
RSV-related MACE
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Laboratory-confirmed mycoplasma infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Laboratory-confirmed HMPV infection
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related tract disease hospitalization/emergency department visit
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Critical lower respiratory tract disease hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Critical respiratory tract disease hospitalization
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related COPD exacerbation
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
All-cause COPD exacerbation
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
Asthma exacerbation
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months
RSV-related asthma exacerbation
Time Frame: ≥14 days after initially booked vaccination/ information visit date up to 8 months
≥14 days after initially booked vaccination/ information visit date up to 8 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Tor Biering-Sørensen

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Pfizer

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Chair: Tor Biering-Sørensen, MD, PhD, MSc, MPH, Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
November 18, 2024

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
May 1, 2028

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
August 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 8, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 9, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2024

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 29, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
October 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DAN-RSV
  • 2024-516600-42-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

In this trial, baseline and endpoint data will be collected from Danish administrative health registries, which are subject to Danish legislation and can only be made available to a third party under certain conditions. Please contact the sponsor-investigator in case of any inquiries.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings